Chugai Pharmaceutical CoCHGCY +0.13%92 OCF Margin % is 37.93% as of Mar. 2026, which is 40% above its 10-year median of 27.01. GuruFocus rates CHGCY with a GF Score™ of 92/100 and a GF Value™ of $24.28 (Fairly Valued). The stock has 1 warning sign investors should review. Among 959 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 94.89% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (CHGCY) has a OCF Margin % of 37.93% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Chugai Pharmaceutical Co and its competitors. This is 40% above median its historical median of 27.01. Over the past decade, Chugai Pharmaceutical Co's OCF Margin % has ranged from 7.89 to 38.24. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #49 out of 959 companies in the Drug Manufacturers industry, placing it in the top 5.1%.
Is Chugai Pharmaceutical Co's OCF Margin % too high?
Chugai Pharmaceutical Co's current OCF Margin % of 37.93% is 40% above median its 10-year median of 27.01. Over the past 10 years, this metric has ranged from a low of 7.89 to a high of 38.24. The Drug Manufacturers industry median OCF Margin % is 9.95. Chugai Pharmaceutical Co's value of 37.93% is 281.2% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #49 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's OCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #49 out of 959 companies for OCF Margin %. This places Chugai Pharmaceutical Co in the top 5% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.95. Chugai Pharmaceutical Co's value of 37.93% is 281.2% above this benchmark. Historically, Chugai Pharmaceutical Co's own OCF Margin % has ranged from 7.89 to 38.24 over the past decade. While the company's 10-year median is 27.01 vs. the industry median of 9.95, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current OCF Margin % of 37.93% is 281.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current OCF Margin % is 37.93%, which is 40% above median its own 10-year median of 27.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCY) is currently considered Fairly Valued. The stock's GF Value™ is $24.28, compared to a current price of $22.99 — trading 5.3% below its estimated fair value. The current OCF Margin % is 37.93%, which is 40% above median its 10-year median of 27.01 and 281.2% above the Drug Manufacturers industry median of 9.95. Chugai Pharmaceutical Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCY), the current OCF Margin % is 37.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCY) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $22.99 is trading 5.3% below its estimated GF Value™ of $24.28.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for CHGCY:
OCF Margin %: 37.93% (40% above median its 10-year median of 27.01)
GF Value™: $24.28 vs. price of $22.99 (5.3% below fair value)
Industry Position: 281.2% above the Drug Manufacturers median (#49 of 959)
No single metric tells the full story. See the CHGCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
92GF Score
Get the complete analysis for CHGCY
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCY has been successfully added to your 
